- Home
- / Aerie Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Aerie Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$15.3
2022-11-22
Market Capitalization
$722.2 M
2022-11-22
Revenue
$194.1 M
FY, 2021
CreditSafe Score
?
Score changed on Apr 22, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.2M | 69.9M | 83.1M | 194.1M | |||||
| Cost of goods sold | 641.0K | 22.8M | 25.3M | 26.8M | |||||
| Gross profit | 23.5M | 47.1M | 57.8M | ||||||
| Gross profit margin, % | 97.3% | 67.4% | 69.5% | ||||||
| General and administrative expense | 73.6M | 120.6M | 138.4M | 137.2M | 137.8M | ||||
| Operating expense total | 145.7M | 233.3M | 234.6M | 213.5M | 213.6M | ||||
| EBIT | (22.2M) | (50.0M) | (75.1M) | (96.9M) | (145.7M) | (209.7M) | (187.5M) | (155.7M) | (46.4M) |
| EBIT margin, % | -867.4% | -268.3% | -187.3% | ||||||
| Pre tax profit | (74.2M) | (98.9M) | (146.9M) | (232.6M) | (199.7M) | (177.9M) | (74.2M) | ||
| Income tax expense | 139.0K | 193.0K | (1.8M) | 3.0K | (90.0K) | 5.2M | 593.0K | ||
| Net Income | (31.1M) | (48.1M) | (74.4M) | (99.1M) | (145.1M) | (232.6M) | (199.6M) | (183.1M) | (74.8M) |